(CLBT) Cellebrite DI - Ratings and Ratios
Forensics, Collection, Analytics, Management, Training
CLBT EPS (Earnings per Share)
CLBT Revenue
Description: CLBT Cellebrite DI
Cellebrite DI Ltd. is a leading provider of digital investigation solutions for law enforcement and government agencies, offering a suite of tools that enable users to access, analyze, and manage digital data throughout the investigative lifecycle. The companys products, such as Inseyets, Cellebrite Pathfinder, Smart Search, and Guardian, cater to various investigative needs, including child exploitation, homicide, and cybercrime.
From a business perspective, Cellebrites revenue growth is likely driven by increasing demand for digital forensics and investigation solutions, particularly in the government and law enforcement sectors. Key Performance Indicators (KPIs) to watch include revenue growth rate, customer acquisition rate, and the average revenue per user (ARPU). The companys ability to expand its product offerings and penetrate new markets will be crucial to its long-term success.
Analyzing Cellebrites financials, we can observe that the company has a significant market capitalization of $3.44 billion, indicating a substantial presence in the industry. The forward P/E ratio of 37.17 suggests that investors expect significant growth in the companys earnings. However, the Return on Equity (RoE) of -81.13 indicates that the company is currently unprofitable, which may be a concern for investors. Key metrics to monitor include the companys quarterly earnings growth, operating margins, and cash flow generation.
To evaluate Cellebrites stock performance, we can examine its trading metrics, such as trading volume, short interest, and institutional ownership. A thorough analysis of these metrics can provide insights into market sentiment and potential price movements. Additionally, comparing Cellebrites valuation multiples to those of its peers in the application software industry can help determine if the stock is undervalued or overvalued.
CLBT Stock Overview
| Market Cap in USD | 4,180m |
| Sub-Industry | Application Software |
| IPO / Inception | 2021-08-31 |
CLBT Stock Ratings
| Growth Rating | 32.7% |
| Fundamental | 83.4% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -16.6% |
| Analyst Rating | 4.75 of 5 |
CLBT Dividends
Currently no dividends paidCLBT Growth Ratios
| Growth Correlation 3m | 43.3% |
| Growth Correlation 12m | -56.8% |
| Growth Correlation 5y | 50.8% |
| CAGR 5y | 59.86% |
| CAGR/Max DD 3y | 1.25 |
| CAGR/Mean DD 3y | 9.95 |
| Sharpe Ratio 12m | -0.10 |
| Alpha | 0.17 |
| Beta | 0.319 |
| Volatility | 40.01% |
| Current Volume | 996.9k |
| Average Volume 20d | 1678.9k |
| Stop Loss | 16.5 (-4.4%) |
| Signal | -0.20 |
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (-150.9m TTM) > 0 and > 6% of Revenue (6% = 26.2m TTM) |
| FCFTA 0.19 (>2.0%) and ΔFCFTA 3.28pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 67.81% (prev 47.45%; Δ 20.36pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.20 (>3.0%) and CFO 161.1m > Net Income -150.9m (YES >=105%, WARN >=100%) |
| Net Debt (-156.9m) to EBITDA (72.4m) ratio: -2.17 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.96 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (249.0m) change vs 12m ago 25.15% (target <= -2.0% for YES) |
| Gross Margin 84.38% (prev 84.19%; Δ 0.19pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 64.99% (prev 65.13%; Δ -0.14pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 0.27 (EBITDA TTM 72.4m / Interest Expense TTM 225.3m) >= 6 (WARN >= 3) |
Altman Z'' 2.21
| (A) 0.38 = (Total Current Assets 606.1m - Total Current Liabilities 310.0m) / Total Assets 787.4m |
| (B) -0.16 = Retained Earnings (Balance) -128.0m / Total Assets 787.4m |
| (C) 0.09 = EBIT TTM 61.9m / Avg Total Assets 672.0m |
| (D) -0.33 = Book Value of Equity -125.3m / Total Liabilities 379.0m |
| Total Rating: 2.21 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 83.35
| 1. Piotroski 4.50pt = -0.50 |
| 2. FCF Yield 3.94% = 1.97 |
| 3. FCF Margin 34.12% = 7.50 |
| 4. Debt/Equity 0.19 = 2.48 |
| 5. Debt/Ebitda 1.07 = 1.67 |
| 6. ROIC - WACC (= 9.46)% = 11.83 |
| 7. RoE -42.94% = -2.50 |
| 8. Rev. Trend 97.32% = 7.30 |
| 9. EPS Trend 72.18% = 3.61 |
What is the price of CLBT shares?
Over the past week, the price has changed by +0.94%, over one month by +6.81%, over three months by +8.01% and over the past year by -1.15%.
Is Cellebrite DI a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CLBT is around 19.36 USD . This means that CLBT is currently undervalued and has a potential upside of +12.17% (Margin of Safety).
Is CLBT a buy, sell or hold?
- Strong Buy: 6
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CLBT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 22.6 | 30.8% |
| Analysts Target Price | 22.6 | 30.8% |
| ValueRay Target Price | 21.3 | 23.4% |
Last update: 2025-09-12 04:33
CLBT Fundamental Data Overview
CCE Cash And Equivalents = 472.2m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 37.1747
P/S = 9.572
P/B = 10.2358
Beta = 1.277
Revenue TTM = 436.7m USD
EBIT TTM = 61.9m USD
EBITDA TTM = 72.4m USD
Long Term Debt = 69.0m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 8.47m USD (from shortTermDebt, last quarter)
Debt = 77.5m USD (Calculated: Short Term 8.47m + Long Term 69.0m)
Net Debt = -156.9m USD (from netDebt column, last quarter)
Enterprise Value = 3.79b USD (4.18b + Debt 77.5m - CCE 472.2m)
Interest Coverage Ratio = 0.27 (Ebit TTM 61.9m / Interest Expense TTM 225.3m)
FCF Yield = 3.94% (FCF TTM 149.0m / Enterprise Value 3.79b)
FCF Margin = 34.12% (FCF TTM 149.0m / Revenue TTM 436.7m)
Net Margin = -34.56% (Net Income TTM -150.9m / Revenue TTM 436.7m)
Gross Margin = 84.38% ((Revenue TTM 436.7m - Cost of Revenue TTM 68.2m) / Revenue TTM)
Tobins Q-Ratio = -30.20 (set to none) (Enterprise Value 3.79b / Book Value Of Equity -125.3m)
Interest Expense / Debt = 1.74% (Interest Expense 1.35m / Debt 77.5m)
Taxrate = 6.32% (1.31m / 20.8m)
NOPAT = 57.9m (EBIT 61.9m * (1 - 6.32%))
Current Ratio = 1.96 (Total Current Assets 606.1m / Total Current Liabilities 310.0m)
Debt / Equity = 0.19 (Debt 77.5m / last Quarter total Stockholder Equity 408.4m)
Debt / EBITDA = 1.07 (Net Debt -156.9m / EBITDA 72.4m)
Debt / FCF = 0.52 (Debt 77.5m / FCF TTM 149.0m)
Total Stockholder Equity = 351.6m (last 4 quarters mean)
RoA = -19.17% (Net Income -150.9m, Total Assets 787.4m )
RoE = -42.94% (Net Income TTM -150.9m / Total Stockholder Equity 351.6m)
RoCE = 14.71% (Ebit 61.9m / (Equity 351.6m + L.T.Debt 69.0m))
RoIC = 16.48% (NOPAT 57.9m / Invested Capital 351.6m)
WACC = 7.02% (E(4.18b)/V(4.26b) * Re(7.12%)) + (D(77.5m)/V(4.26b) * Rd(1.74%) * (1-Tc(0.06)))
Shares Correlation 3-Years: 72.73 | Cagr: 2.33%
Discount Rate = 7.12% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈124.2m ; Y1≈153.2m ; Y5≈261.5m
Fair Price DCF = 18.19 (DCF Value 4.45b / Shares Outstanding 244.5m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 72.18 | EPS CAGR: 146.8% | SUE: 0.47 | # QB: 0
Revenue Correlation: 97.32 | Revenue CAGR: 18.11% | SUE: N/A | # QB: None
Additional Sources for CLBT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle